More recently, cabozantinib (1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide) has been tested in RET overexpressing cell cultures and PDXs from resected brain metastases, determining a reduction of RET phosphorylation and inhibiting tumor growth (52). Here, RET is linked to neoplasm.